Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maju Mathews

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Neuropsychiatric Disease and Treatment|July 22, 2021
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled TrialsBettina Diekamp, Stephane Borentain, Dong-Jing Fu, et al.
International Clinical Psychopharmacology|May 25, 2017
Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trialsMichael E Thase, John Edwards, Suresh Durgam, et al.
Journal of Psychopharmacology (Oxford, England)|October 11, 2022
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder"Stephane Borentain, Pooja Desai, Dong-Jing Fu, et al.
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.
CNS Spectrums|November 9, 2016
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active controlRonald Landbloom, Mary Mackle, Xiao Wu, et al.
Therapeutic Advances in Psychopharmacology|February 21, 2022
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomesKatalin Pungor, Vasilis P Bozikas, Robin Emsley, et al.
Neuropsychiatric Disease and Treatment|June 16, 2022
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant DepressionJoachim Morrens, Maju Mathews, Vanina Popova, et al.
International Clinical Psychopharmacology|September 20, 2016
Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled studyAnita H Clayton, Suresh Durgam, Dayong Li, et al.
Journal of Affective Disorders|October 27, 2015
Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorderRonald L Landbloom, Mary Mackle, Xiao Wu, et al.
CNS Drugs|November 26, 2024
Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An OverviewChristoph U Correll, Edward Kim, Jennifer Kern Sliwa, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Neuropsychiatric Disease and Treatment|July 22, 2021
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled TrialsBettina Diekamp, Stephane Borentain, Dong-Jing Fu, et al.
International Clinical Psychopharmacology|May 25, 2017
Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trialsMichael E Thase, John Edwards, Suresh Durgam, et al.
Journal of Psychopharmacology (Oxford, England)|October 11, 2022
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder"Stephane Borentain, Pooja Desai, Dong-Jing Fu, et al.
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.
CNS Spectrums|November 9, 2016
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active controlRonald Landbloom, Mary Mackle, Xiao Wu, et al.
Therapeutic Advances in Psychopharmacology|February 21, 2022
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomesKatalin Pungor, Vasilis P Bozikas, Robin Emsley, et al.
Neuropsychiatric Disease and Treatment|June 16, 2022
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant DepressionJoachim Morrens, Maju Mathews, Vanina Popova, et al.
International Clinical Psychopharmacology|September 20, 2016
Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled studyAnita H Clayton, Suresh Durgam, Dayong Li, et al.
Journal of Affective Disorders|October 27, 2015
Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorderRonald L Landbloom, Mary Mackle, Xiao Wu, et al.
CNS Drugs|November 26, 2024
Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An OverviewChristoph U Correll, Edward Kim, Jennifer Kern Sliwa, et al.
Pageof 10